Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

Fuda Cancer Hospital, Guangzhou40 enrolled

Overview

In this study, effects of γδT cells on human hepatocellular liver cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Liver tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Liver Cancer

Interventions

DC-CIK cellsBIOLOGICAL

DC-CIK cells will be used against tumor cells.

γδ T cellsBIOLOGICAL

γδ T cells will be used against breast tumor.

γδ T/DC-CIK cellsBIOLOGICAL

γδ T/DC-CIK cells will be used against breast tumor.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age:18-75 2. Karnofsky performance status \>50 3. Diagnosis with hepatocellular carcinoma cancer based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive cryosurgery, gd Tcells/ DC-CIK. 6. Life expectancy: Greater than 3 months 7. Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: 1. Patients with other kinds of cancer 2. History of coagulation disorders or anemia 3. Patients with heart disease and diabetes

Locations (1)

Biological treatment center in Fuda cancer hospital

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Reduced size of the tumors

Time frame: Up to one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.